Advanced search
Publication Cover
International Journal of General Medicine Volume 14, 2021 - Issue
Submit an article Journal homepage
146
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer

Yi Li1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Cheng Liu2 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;3 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;4 Center for Biomedical Imaging, Fudan University, Shanghai, People’s Republic of China;5 Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, People’s Republic of China;6 Department of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Shanghai, People’s Republic of ChinaView further author information
,
Bibo Wang7 Orthopaedic Department, Shanghai Ruijin Hospital, Shanghai Jiaotong University Medicine School, Shanghai, People’s Republic of ChinaView further author information
,
Xichun Hu1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Chengcheng Gong1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Yannan Zhao1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Yizhao Xie1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Yingjian Zhang2 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;3 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;4 Center for Biomedical Imaging, Fudan University, Shanghai, People’s Republic of China;5 Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, People’s Republic of China;6 Department of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Shanghai, People’s Republic of ChinaView further author information
,
Shaoli Song2 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;3 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;4 Center for Biomedical Imaging, Fudan University, Shanghai, People’s Republic of China;5 Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, People’s Republic of China;6 Department of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Shanghai, People’s Republic of ChinaView further author information
,
Zhongyi Yang2 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;3 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;4 Center for Biomedical Imaging, Fudan University, Shanghai, People’s Republic of China;5 Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, People’s Republic of China;6 Department of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Biyun Wang1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1797-1809 | Published online: 11 May 2021

References

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
  • Brewster AM, Hortobagyi GN, Broglio KR, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100(16):1179–1183. doi:10.1093/jnci/djn233
  • Howlader NN, Noone AM, Krapcho M et al. SEER cancer statistics review, 1975–2013 (based on November 2015 SEER data submission, posted to the SEER web site, 2016). 2016. Available from: http://seer.cancer.gov/csr/1975_2013/. Accessed May 1, 2021.
  • Deluche E, Antoine A, Bachelot T, et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. Eur J Cancer. 2020;129:60–70. doi:10.1016/j.ejca.2020.01.016
  • Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi:10.1038/35021093
  • Kim SJ, Lee SW. Diagnostic accuracy of (18)F-FDG PET/CT for detection of peritoneal carcinomatosis; a systematic review and meta-analysis. Br J Radiol. 2018;91(1081):20170519. doi:10.1259/bjr.20170519
  • Kadoya T, Aogi K, Kiyoto S, Masumoto N, Sugawara Y, Okada M. Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study. Breast Cancer Res Treat. 2013;141(2):269–275. doi:10.1007/s10549-013-2687-7
  • Aogi K, Kadoya T, Sugawara Y, et al. Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer. Breast Cancer Res Treat. 2015;150(1):209–217. doi:10.1007/s10549-015-3303-9
  • Morris PG, Ulaner GA, Eaton A, et al. Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. Cancer-Am Cancer Soc. 2012;118(22):5454–5462.
  • Son SH, Kim DH, Hong CM, et al. Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast. Bmc Cancer. 2014;14:585. doi:10.1186/1471-2407-14-585
  • Ha S, Park S, Bang JI, Kim EK, Lee HY. Metabolic radiomics for pretreatment (18)F-FDG PET/CT to characterize locally advanced breast cancer: histopathologic characteristics, response to neoadjuvant chemotherapy, and prognosis. Sci Rep. 2017;7(1):1556. doi:10.1038/s41598-017-01524-7
  • Huyge V, Garcia C, Alexiou J, et al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Oncol. 2010;22(10):818–827. doi:10.1016/j.clon.2010.05.021
  • Bural G, Torigian DA, Houseni M, Basu S, Srinivas S, Alavi A. Tumor metabolism measured by partial volume corrected standardized uptake value varies considerably in primary and metastatic sites in patients with lung cancer. A new observation. Hell J Nucl Med. 2009;12(3):218–222.
  • Salamon J, Derlin T, Bannas P, et al. Evaluation of intratumoural heterogeneity on (1)(8)F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur J Nucl Med Mol Imaging. 2013;40(5):685–692. doi:10.1007/s00259-012-2314-6
  • Tahari AK, Alluri KC, Quon H, Koch W, Wahl RL, Subramaniam RM. FDG PET/CT imaging of oropharyngeal squamous cell carcinoma: characteristics of human papillomavirus-positive and -negative tumors. Clin Nucl Med. 2014;39(3):225–231. doi:10.1097/RLU.0000000000000255
  • Cokmert S, Tanriverdi O, Karapolat I, et al. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: an Izmir oncology group study. J Buon. 2016;21(6):1410–1418.
  • Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195(2):310–320. doi:10.2214/AJR.10.4923
  • Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2(3):159–171. doi:10.1016/S1095-0397(99)00016-3
  • Ulaner GA, Eaton A, Morris PG, et al. Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Med. 2013;2(5):725–733. doi:10.1002/cam4.119
  • Fonti R, Larobina M, Del VS, et al. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53(12):1829–1835. doi:10.2967/jnumed.112.106500
  • Zhu D, Ma T, Niu Z, et al. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer. 2011;73(3):332–337. doi:10.1016/j.lungcan.2011.01.007
  • Yang Z, Shi Q, Zhang Y, et al. Pretreatment (18)F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma–a retrospective study. Radiat Oncol. 2015;10:4. doi:10.1186/s13014-014-0268-5
  • Win T, Miles KA, Janes SM, et al. Tumor heterogeneity and permeability as measured on the CT component of PET/CT predict survival in patients with non-small cell lung cancer. Clin Cancer Res. 2013;19(13):3591–3599. doi:10.1158/1078-0432.CCR-12-1307
  • De Palma M, Hanahan D. The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol. 2012;6(2):111–127. doi:10.1016/j.molonc.2012.01.011
  • Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805(1):105–117. doi:10.1016/j.bbcan.2009.11.002
  • Zhang J, Jia Z, Ragaz J, et al. The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer. Bmc Cancer. 2013;13:42. doi:10.1186/1471-2407-13-42
  • Jimenez-Ballve A, Garcia GM, Salsidua-Arroyo O, et al. Prognostic value of metabolic tumour volume and total lesion glycolysis in (18)F-FDG PET/CT scans in locally advanced breast cancer staging. Rev Esp Med Nucl Imagen Mol. 2016;35(6):365–372. doi:10.1016/j.remn.2016.01.007
  • Marinelli B, Espinet-Col C, Ulaner GA, et al. Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. Am J Nucl Med Mol Imaging. 2016;6(2):120–127.
  • Gong C, Ma G, Hu X, et al. Pretreatment (18)F-FDG uptake heterogeneity predicts treatment outcome of first-line chemotherapy in patients with metastatic triple-negative breast cancer. Oncologist. 2018;23(10):1144–1152. doi:10.1634/theoncologist.2018-0001

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.